Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen

Publisher： Karger

E-ISSN： 1664-5529|1|1|45-54

ISSN： 1664-5529

Source： Nephron Extra, Vol.1, Iss.1, 2011-08, pp. : 45-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Therapeutic Potential of Erythropoiesis-Stimulating Agents for Tissue Protection: A Tale of Two Receptors

By  

Blood Purification, Vol. 29, Iss. 2, 2010-01 ,pp. : 86-92

Karger

Access to resources Recommend Favorite

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

By  

American Journal of Nephrology, Vol. 45, Iss. 3, 2017-02 ,pp. : 235-247

Karger

Access to resources Recommend Favorite

Possible Inhibitory Effect of Erythropoiesis-Stimulating Agents at the Predialysis Stage on Early-Phase Coronary Events after Hemodialysis Initiation

By  

Cardiorenal Medicine, Vol. 7, Iss. 1, 2016-08 ,pp. : 21-30

Karger

Access to resources Recommend Favorite

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

By  

Cardiorenal Medicine, Vol. 7, Iss. 3, 2017-04 ,pp. : 188-197

Karger

Access to resources Recommend Favorite

Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?

By  

Cardiorenal Medicine, Vol. 2, Iss. 1, 2011-12 ,pp. : 18-25

Karger

Access to resources Recommend Favorite